• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Omega-3 fatty acid supplements not helpful for CVD prevention, JAMA reports

News
Article

Treatment with omega-3 polyunsaturated fatty acides to prevent cardiovascular disease (CVD) has been controversial. A recent meta-analysis and review showed that overall, omega-3 PUFA supplementation did not lower the risk of CVD, according to data published in the Sept. 12, 2012 issues of JAMA.

Treatment with omega-3 polyunsaturated fatty acids (PUFAs) to prevent cardiovascular disease (CVD) has been controversial. A recent meta-analysis and review showed that overall, omega-3 PUFA supplementation did not lower the risk of CVD, according to data published in the Sept. 12, 2012 issue of JAMA.

Evangelos C. Rizos, MD, PhD, and colleagues conducted a literature review and included data from 20 randomized studies of 68,680 patients, who received omega-3 as supplements or through dietary counseling. All but 2 trials were based on omega-3 supplementation with a mean omega-3 dose of 1.51 g per day. In 10 studies, the omega-3 dose was 1 g or greater per day. Median duration was 2 years and the maximum was 6.2 years. In most cases, omega-3 PUFAs were administered for secondary CVD prevention, the authors noted.

“Overall, omega-3 PUFA supplements were not statistically significantly associated with a reduced all-cause mortality (RR, 0.96; 95% CI, 0.91 to 1.02; P=.17),” the authors said. In the all-cause mortality review, 17 studies were included for a total of 6,295 events in a group of 63,279 participants.

In a review of 13 studies, 3,480 cardiac deaths occurred in a group of 56,407 participating. Again, omega-3 supplements were not helpful, showing no statistically significant association for supplementation and cardiac death (RR, 0.91; 95% CI, 0.85 to 0.98; P=.01), the article noted.

The authors also found that omega-3 supplementation did not reduce the rates of sudden death, according to 7 studies of 41,751 patients and 1,030 events (RR, 0.87; 95% CI, 0.75 to 1.01; P=.06). Supplementation did not reduce the risk of myocardial infarction, which included 13 studies of 53,875 patients (RR, 0.89; 95% CI, 0.76 to 1.04; P=.14), or stroke, which included data from 9 studies of 52,589 patients (RR, 1.05; 95% CI, 0.93 to 1.18; P=.47).

“Our findings do not justify the use of omega-3 as a structured intervention in everyday clinical practice or guidelines supporting dietary omega-3 PUFA administration,” the authors concluded.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.